Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jincao Tablet Phase III Trial in Chronic Pelvic Pain After Pelvic Inflammatory Disease
CTR20222693Phase 3Completed
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Nov 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic prostatitis (CP) comparing Jincao Tablet with Placebo (Jincao Tablet mimetic) (2 arms). Primary endpoint: Pain VAS score. Started Nov 2022; status: completed.
02
Drugs
Jincao
03
Conditions
chronic prostatitis (CP)
Beyond the preview
Go deeper on CTR20222693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222693.